3 completed, 2 recruiting, 2 terminated, 1 active not recruiting. 4 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 2, Active not recruiting 1, Withdrawn 1 |
| Phase 3 | 3 | Completed 2, Terminated 1 |
Follow AGO Research GmbH: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy Pembrolizumab, Lenvatinib - Recurrent Vulvar Cancer, Persistent Vulvar Cancer | Phase 2 | Recruiting | AGO Research GmbH | 42 | 2025-06-24 | 2026-05-11 |
| Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi Niraparib, Dostarlimab - Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer | Phase 2 | Withdrawn | AGO Research GmbH | 2023-11-01 | 2025-04-06 | |
| Association of Ex Vivo Drug Response (EVDR) and Clinical Outcome in Ovarian Cancer Biological sample collection - Epithelial Ovarian Cancer | Terminated | Exscientia AI Limited | 13 | 2023-04-14 | 2024-09-26 | |
| WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC olaparib, durvalumab - Epithelial Ovarian Cancer | Phase 2 | Recruiting | AGO Research GmbH | 60 | 2022-05-05 | 2025-10-03 |
| Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer Carboplatin, Pegylated liposomal doxorubicin (PLD), Gemcitabine - Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma | Phase 2 | Active not recruiting | AGO Research GmbH | 136 | 2021-10-13 | 2026-05-13 |
| Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer Carboplatin, Gemcitabine, Bevacizumab - Recurrent Ovarian Carcinoma | Phase 3 | Terminated | AGO Research GmbH | 9 | 2019-08-09 | 2022-02-24 |
| Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer Bevacizumab, Atezolizumab, Chemotherapy - Recurrent Ovarian Carcinoma | Phase 3 | Completed | AGO Research GmbH | 574 | 2018-09-11 | 2025-04-06 |
| Prevalence of BRCA in Patients With Ovarian Cancer Testing of BRCA status regarding germline and somatic mutation - BRCA Status, Ovarian Cancer | Completed | AGO Research GmbH | 530 | 2015-03-01 | 2021-06-16 | |
| Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer Carboplatin, PLD, Bevacizumab - Recurrent Platinum-sensitive Ovarian Cancer | Phase 3 | Completed | AGO Research GmbH | 682 | 2013-05-01 | 2021-07-13 |
Ovarian Neoplasms (5) · Carcinoma, Ovarian Epithelial (2) · Fallopian Tube Neoplasms (1) · Vulvar Neoplasms (1)
Bevacizumab (3) · Carboplatin (3) · 1-dodecylpyridoxal (2) · Gemcitabine (2) · Paclitaxel (2) · Cisplatin (1) · Drug Therapy (1) · Trabectedin (1) · atezolizumab (1) · dostarlimab (1) · durvalumab (1) · lenvatinib (1) · liposomal doxorubicin (1) · mirvetuximab soravtansine (1) · niraparib (1)
Germany (8) · Austria (3) · Belgium (2) · France (2) · Australia (1) · Denmark (1) · Estonia (1) · Finland (1) · Lithuania (1) · Norway (1) · Spain (1) · Sweden (1) · Switzerland (1) · United Kingdom (1)
Felix Hilpert, MD, PhD (1) · Jacobus Pfisterer, PhD MD (1) · Nikolaus Krall, Dr. (1) · Philipp Harter (1) · Philipp Harter, MD, PhD (1) · Philipp Harter, PhD MD (1)
PMID 30979843, PMID 32305099, PMID 32606097, PMID 33273034, PMID 34593530, PMID 34963005, PMID 41337696, PMID 42284542
2018 (1)